StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3046% below fair value
$0.87−0.03 (-3.03%)

Close on Nov 18, 2026Market cap $50.90MP/E 21.9Yield –

Spero Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Spero Therapeutics

Spero Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Spero Therapeutics figures

See a number that looks wrong?